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Abstract
Background: Recently, breast cancer incidence and prevalence has been increasing. Patients' health related quality
of life is important considerations in the treatment of breast cancer. The EQ-5D-3L is one of most popular
instruments to measure health related quality of life. This study was aimed to evaluate the validity and reliability of
EQ-5D-3L in post-operative breast cancer patients from Korea.
Methods: A total of 827 patients visiting the ambulatory cancer center of 1 tertiary hospital after breast cancer
surgery self-administered the EQ-5D-3L and Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B). We
evaluated known-group validity using differences in the EQ-5D-3L index and EQ-VAS score according to
demographic and clinical data. The discriminatory ability of the EQ-5D-3L was determined by comparing the mean
FACT-B subscale scores between subjects with no problems and subjects with moderate or severe problems in
each EQ-5D-3L dimension. Construct validity was evaluated by Pearson correlation coefficients among the EQ-5D-3L
index and FACT-B subscales, respectively. Reliability was assessed in terms of test-retest reliability using Cohen’s
kappa value and intra-class correlation coefficient (ICC).
Results: The EQ-5D-3L index and EQ-VAS score were higher in the educated, current radiotherapy and
unmarried groups. The correlation of EQ-5D-3L index and subscales for the FACT-B was highest in physical
well-being (r = 0.553) and lowest in social well-being (r = 0.199). For reliability, the Kappa values’ range was
from 0.32 to 0.70, and ICCs of the EQ-5D-3L index and EQ-VAS scores were 0.70 and 0.48, respectively.
Conclusions: This study indicated that the EQ-5D-3L could be a valid health related quality of life instrument
for postoperative breast cancer patients.
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Background
Breast cancer is the most frequently diagnosed cancer in
females and the leading cause of cancer-related deaths in
both economically developed and developing countries
[1]. In Korea, the crude breast cancer incidence rate was
63.7 per 100,000 persons in 2011 and has been increas-
ing since 1999 [2]. The 5-year survival rate for breast
cancer patients has improved, with 91.3 % reported
between 2007 and 2011 in Korea [2]. Recent years have
led to a range of treatments for breast cancer, and devel-
opment of additional therapeutics is continually in
progress.
Health-related quality of life (HRQoL) and traditional
clinical outcomes (i.e., survival rate or tumor responses)
are considered as significant outcomes of cancer care [3].
Tools to assess HRQoL are classified into disease-specific
instruments and generic instruments. Preference-based
instruments (the Health Utility Index [4, 5], the EuroQol
5D (EQ-5D-3L) [6], or the Short Form 6D [7]) are generic
instrument generating utilities that yield a measure that
combines both the length and quality of life [8]. Disease-
specific instruments can be more sensitive for detecting
clinically important differences or changes in specific dis-
ease groups in general, although general instrument is oc-
casionally not inferior to disease-specific instrument [9].
However, they do not compare HRQoL of patients with
other diseases [8]. Resource allocation for health care has
been a critical issue, not only for its effectiveness, but also
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for efficiency of care; hence, it is important for guiding
healthcare policy.
The EQ-5D-3L, a generic preference-based instrument
that is widely used to measure HRQoL, can be used to
assign preference values to various health states [10].
Additionally, EQ-5D-3L is a unique instrument with
quality weight tariffs for use in Korean populations [11].
The psychometric properties of the Korean EQ-5D-3L
have been studied for rheumatic disease [12] and colon
cancer [13] patients. However, studies on validity and re-
liability of the EQ-5D-3L in breast cancer patients in
Korea are scarce [14]. Hence, we evaluated the validity
and reliability of the EQ-5D-3L to measure the HRQoL
in post-operative breast cancer patients from Korea.
Methods
Subjects and settings
A consecutive series of breast cancer patients who had
surgery as a primary treatment at the ambulatory cancer
center of 1 tertiary hospital in Seoul, Korea from Febru-
ary 2012 to May 2012, participated in this study. All par-
ticipants provided informed written consent prior to
taking our survey and a total of 1,002 subjects were con-
secutively recruited. The initial 150 recruited subjects
were requested to complete an EQ-5D-3L questionnaire
1 week later via mail to assess the test-retest reliability
of each patient. The survey was self-administered in the
waiting room at the center with or without research
nurse assistance. The Institutional Review Board of
Asan Medical Center approved the study (IRB approval
number: 2012–0010).
Information
Our questionnaire included requests for demographic
information (age, sex, level of education, marital status,
and occupation) and 2 HRQOL instruments (EQ-5D-3L
and Functional Assessment of Cancer Therapy-Breast
Cancer [FACT-B] version 4). Clinical information (the
type of surgery, American Joint Committee on Cancer
[AJCC] 7th stage at diagnosis, duration of disease since
diagnosis, and current treatment for breast cancer), was
obtained from the cancer registry database of the center.
The EQ-5D-3L is an instrument widely used to
measure and evaluate the general health status of a
patient in 5 dimensions (mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depression) with
3 levels as follows: 1, no problems; 2, some or moderate
problems; and 3, extreme problems. The EQ-5D-3L pro-
vides a simple descriptive profile and a single index of
health status [10]. The EQ-VAS records the respondent’s
self-rated health on a vertical, visual analogue scale
where the endpoints are classified as follows: ‘best
imaginable health state’ =100 and ‘worst imaginable
health state’ =0 [10].
The FACT-B is a validated multi-dimensional self-
reported questionnaire with a 36-item questionnaire that
measures both the 27-item general QoL associated with
cancer (Functional Assessment of Cancer Therapy -
General [FACT-G]) and an additional 9-item breast
cancer-related QOL. The FACT-B includes the following
subscales that measure physical well-being (PWB), func-
tional well-being (FWB), emotional well-being (EWB),
social/family well-being (SWB), and the breast cancer
subscale (BCS). FACT-B total scores were calculated as
the sum of the 5 subscales. FACT-G scores were calcu-
lated as the sum of the PWB, FWB, EWB, and SWB
scores and FACT-B Trial Outcome Index (TOI) was cal-
culated as the addition of the PWB, FWB and BCS
scores [15, 16]. This study used the Korean FACT-B ver-
sion 4 that is validated [17] and a higher score indicated
a better state.
Analyses
The proportion of patients reporting any problems in each
EQ-5D-3L dimension and EQ-5D-3L index were presented.
The EQ-5D-3L index was calculated using a Korean valu-
ation set [11]. The EQ-5D-3L index ranged from −0.171 to
1, and higher values indicated better health status. The
FACT-B subscale scores were calculated in accordance with
a scoring guideline provided by the Functional Assessment
of Chronic Illness Therapy (FACIT) measurement system
(www.facit.org/FACITOrg).
Differences in the EQ-5D-3L index and EQ-VAS score
according to demographic and clinical data were com-
pared using the Student’s t-test or analysis of variance
(ANOVA). In aspects of known group validity, we ex-
pected that the EQ-5D-3L index and EQ VAS would be
lower for the following conditions: worse stage at diag-
nosis [18], current treatment group [18–20], shorter dur-
ation of disease since diagnosis [19, 21–24], older age
group [16, 22], and lower education group [16, 18, 22].
The discriminatory ability of the EQ-5D-3L was deter-
mined by comparing the mean FACT-B subscale scores
between subjects with no problems and subjects with
moderate or severe problems in each EQ-5D-3L dimen-
sion. It was expected that the FACT-B subscale scores of
subjects with no problem would be higher than those of
subjects with any problem. The mean differences in the
FACT-B subscale were compared using the Student’s
t-test. Discriminatory ability of the EQ-5D-5 L was
considered acceptable when all hypothesized differ-
ences were significant.
Construct validity was evaluated by Pearson correl-
ation coefficients among the EQ-5D-3L index, EQ-VAS,
and FACT-B subscales. EQ-5D-3L index and FACT-G
total scores were expected to be moderately or strongly
correlated, because both instruments measured HRQoL.
It was expected that the correlations between the
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EQ-5D-3L index and SWB subscale would be weaker
than those of the other FACT-B subscales, because
the EQ-5D-3L does not contain a social dimension.
Construct validity was considered as acceptable when
the hypotheses were satisfied.
Cohen’s kappa statistic was used to assess the test-
retest reliability of each dimension for the EQ-5D-3L in-
strument. The kappa statistic calculates the degree of
agreement in classification over that which would be ex-
pected by chance. There is no universally agreed-upon
criteria of significant kappa value. We considered
test-retest reliability of EQ-5D-5 L as acceptable if
kappa value was higher than 0.4 in each dimension
[25]. The intraclass correlation coefficient (ICC) [26]
was used to assess the reliability of the EQ-5D-3L
index and EQ-VAS score. We considered that > 0.5
ICC was acceptable.
Results
Among 1,002 recruited patients with breast cancer, 175
patients were excluded from this analysis: 13 duplicated,
2 with missing EQ-5D-3L data, and 160 patients who
did not merge into the cancer registry data. Thus, a total
of 827 patients were included in the study cohort.
Among 150 participants who completed a second survey
1 week later, 67 participants replied and 54 subjects were
used for test-retest reliability after excluding 13 partici-
pants for whom clinical information was not available.
Demographic characteristics of the survey participants
were shown in Table 1. All study participants were
Table 1 General and clinical characteristics of the study subjects
Variables N (%)
Age, years
Less than 40 54 (6.5)
40–49 263 (31.8)
50–59 385 (46.6)
60 or more 125 (15.1)
Level of education
Elementary school 36 (4.4)
Middle school graduate 80 (9.7)
High school graduate 338 (40.9)








Breast conserving surgery 524 (63.4)








Duration of disease since diagnosis
<1 year 147 (17.8)
1 - < 2 years 104 (12.6)
2 - < 3 years 106 (12.8)
3 - < 4 years 125 (15.1)
4 - < 5 years 91 (11.0)
≥5 years 254 (30.7)
Table 2 Distribution of EQ-5D-3L problem reporting and FACT-
B scores
EQ-5D-3L dimension Levela N (%)
Mobility 1 760 (91.9)
2 67 (8.1)
3 0 (0.0)
Self-care 1 791 (95.7)
2 33 (4.0)
3 3 (0.4)
Usual activities 1 720 (87.1)
2 105 (12.7)
3 2 (0.2)
Pain/discomfort 1 467 (56.5)
2 351 (42.4)
3 9 (1.1)
Anxiety/depression 1 484 (58.5)
2 334 (40.4)
3 0 (1.1)
FACT-B scale scores (possible range) Mean (SD)
Physical well-being (0–28) 24.0 (4.3)
Social well-being (0–28) 17.0 (6.9)
Functional well-being (0–28) 19.3 (6.4)
Emotional well-being (0–24) 18.3 (4.0)
Breast cancer subscale (0–36) 23.3 (5.4)
FACT-G (0–108) 78.7 (15.8)
FACT-B Trial Outcome Index (0–92) 66.7 (12.3)
FACT-B total score (0–144) 102.1 (19.0)
FACT-B functional assessment of cancer therapy—Breast cancer
FACT-G functional assessment of cancer therapy—General
Higher scores on the FACT-B scales indicate better quality of life
a1: no problem; 2: moderate problems; 3: extreme problems
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female with a mean age of 52.1 years. Most patients were
married. The number of participants who had under-
gone breast-conserving surgery was 524 (63.4 %).
The proportion of patients reporting any problems of
the EQ-5D-3L and the FACT-B subscale score distribu-
tion in the study participants was shown in Table 2. The
proportion of patients reporting any problems was
relatively higher in the pain/discomfort and anxiety/de-
pression dimensions at 43.5 % and 41.5 %, respectively.
The mean FACT-G score was 78.7 (SD 15.8) and mean
TOI was 66.7 (12.3). The EQ-5D-3L index and VAS
score according to demographic and clinical features
were shown in Table 3. In the highly educated and un-
married group, and not in current radiotherapy group,
Table 3 EQ-5D-3L scores according to general and clinical characteristics of the study patients
Variables EQ-5D-3L index EQ-VAS
(n = 827) n M SD p-value* M SD p-value*
Age group (year)
Less than 40 54 0.918 (0.071) 0.448 76.3 (18.0) 0.338
40–49 263 0.921 (0.075) 77.8 (17.5)
50–59 385 0.912 (0.092) 78.5 (16.3)
60 or more 125 0.907 (0.105) 80.6 (15.8)
Level of education (year)
≤6 36 0.864 (0.099) <0.001 81.9 (16.0) 0.629
7–9 80 0.880 (0.100) 77.7 (16.8)
10–12 338 0.916 (0.090) 78.2 (17.9)
≥13 371 0.925 (0.079) 78.4 (15.8)
Marital status
Married 692 0.917 (0.086) 0.045 78.6 (16.7) 0.697
Widowed 45 0.901 (0.097) 79.0 (15.4)
Divorced 39 0.879 (0.125) 78.1 (20.0)
Unmarried 51 0.921 (0.072) 75.7 (16.2)
Surgery
Mastectomy 303 0.915 (0.088) 0.872 78.8 (16.9) 0.678
Breast conserving surgery 524 0.914 (0.088) 78.2 (16.6)
AJCC 7th stage at diagnosis
0 136 0.925 (0.081) 0.083 78.2 (16.3) 0.929
1 361 0.918 (0.093) 78.1 (16.6)
2 260 0.909 (0.083) 79.0 (16.4)
3 68 0.895 (0.088) 78.4 (19.1)
Current chemotherapy
No 793 0.915 (0.088) 0.361 78.5 (16.6) 0.602
Yes 26 0.899 (0.081) 76.7 (18.9)
Current radiotherapy
No 764 0.917 (0.087) 0.001 78.8 (16.3) 0.047
Yes 55 0.877 (0.102) 72.8 (21.0)
Duration of disease since diagnosis
<1 year 147 0.893 (0.090) 0.003 77.5 (18.1) 0.385
1 - < 2 years 104 0.903 (0.084) 76.7 (16.7)
2 - < 3 years 106 0.921 (0.093) 78.2 (17.5)
3 - < 4 years 125 0.914 (0.090) 78.5 (16.1)
4 - < 5 years 91 0.934 (0.066) 81.8 (13.9)
≥5 years 254 0.922 (0.090) 78.6 (16.9)
*p < 0.05 by Student’s t-test or ANOVA
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the EQ-5D-3L index scores were higher than corre-
sponding scores of the other groups. A worse stage at
the time of diagnosis was associated with lower HRQoL
scores; however, this trend did not reach the threshold
for statistical significance. By post-hoc analysis, individ-
uals with < 1 year since the time of diagnosis had a sig-
nificantly lower EQ-5D-3L index as compared with
those who had > 4 years since their diagnosis. The EQ-
VAS score were not significantly different according to
demographic and clinical characteristics.
FACT-B subscale scores and summary measurements
by dimension and level of the EQ-5D-3L were shown in
Table 4. All FACT-B subscale scores and combined
index of subjects with no problem were significantly
higher than those of subjects with any problem in all
EQ-5D-3L dimensions. Difference in PWB scores was
larger than other FACT-B subscales in mobility dimen-
sion, whereas difference in PWB scores was larger in
self-care and usual activities dimensions. Difference in
EWB scores was the largest in the anxiety/depression di-
mension. Table 5 showed correlation coefficients among
the EQ-5D-3L index, EQ-VAS score, and FACT-B
scores. TOI scores showed the highest correlation with
both the EQ-5D-3L index and EQ-VAS scores at 0.557
and 0.456, respectively, and the SWB scores showed the
lowest correlation with the EQ-5D-3L index. Rates of
agreements in the EQ-5D-3L dimensions ranged from
85.2 to 96.3 % across dimensions. Kappa statistics ranged
from 0.32 in mobility to 0.70 in pain/discomfort and
anxiety/depression dimensions. ICCs of the EQ-5D-3L
index and EQ-VAS scores were 0.70 and 0.48, respect-
ively (Table 6).
Discussion
In this study, we aimed to assess the validity and reliabil-
ity of EQ-5D-3L for measuring HRQoL in post-operative
breast cancer patients. Our findings supported the valid-
ity of the EQ-5D-3L index. Values for this index were
lower in the current radiation therapy, shorter duration
of disease since diagnosis, and low education groups.
Table 4 FACT-B scales and summary measurements by EQ-5D-3L dimension and level
Dimension Levela n PWB SWB EWB FWB FACTG BCS TOI FACT-B total
Mobility 1 760 24.4** 17.1** 18.5** 19.6** 79.7** 23.7** 67.7** 103.4**
2 or 3 67 19.7 14.9 16.8 16.1 67.6 19.6 55.5 87.3
Self-care 1 791 24.2** 17.1* 18.4* 19.6** 79.4** 23.5** 67.3** 102.9**
2 or 3 36 20.0 14.1 17.0 13.7 64.0 20.5 53.5 84.4
Usual activities 1 720 24.7** 17.3** 18.6** 20.0** 80.7** 23.8** 68.5** 104.5**
2 or 3 107 19.8 14.6 16.3 14.5 65.4 20.0 54.4 85.5
Pain/discomfort 1 467 25.4** 17.5* 18.9** 20.4** 82.3** 24.4** 70.2** 106.7**
2 or 3 360 22.2 16.3 17.6 17.9 74.1 22.0 62.1 96.0
Anxiety/depression 1 484 25.3** 18.0** 20.0** 21.2** 84.6** 24.9** 71.4** 109.5**
2 or 3 343 22.2 15.5 15.9 16.6 70.4 21.1 60 91.6
FACT-B functional assessment of cancer therapy—Breast cancer, FACT-G functional assessment of cancer therapy—general, PWB physical well-being, FWB
functional well-being, EWB emotional well-being, SWB social/family well-being (SWB), BCS breast cancer subscale, TOI Trial outcome index
a1,no problem; 2,moderate problems; 3,extreme problems
*p < 0.05 by Student’s t-test
**p < 0.001 by Student’s t-test
Table 5 Correlations between the EQ-5D-3L index, EQ-VAS
score, and FACT-B scores
FACT-B scores EQ-5D-3L index EQ VAS
Physical well-being 0.553 0.447
Social well-being 0.199 0.170
Emotional well-being 0.400 0.371
Functional well-being 0.377 0.312
Breast cancer subscale 0.390 0.323
FACTG 0.488 0.414
Trial Outcome Index 0.557 0.456
FACT B total 0.516 0.436
FACT-B functional assessment of cancer therapy—breast cancer, FACT-G
functional assessment of cancer therapy—general
Pearson’s correlation coefficient, all p-values were <0.001
Table 6 Test-retest reliability of the EQ-5D-3L
Dimension Kappa statistics (95 % CI)
all patients (n = 54)
Agreement
rate (%)
Mobility 0.32 (−0.18–0.93) 94.4
Self-care 0.49 (−0.11–1.00) 96.3
Usual activities 0.46 (0.13–0.80) 87.0
Pain/discomfort 0.70 (0.51–0.89) 85.2
Anxiety/depression 0.70 (0.52–0.89) 85.2
Intraclass correlation coefficient (95 % CI)
EQ-5D-3L index 0.70 (0.54–0.82)
EQ-VAS 0.48 (0.25–0.66)
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Most of known-group validity features fulfilled our hy-
pothesis. EQ-5D-3L indexes were lower for progressive
stages at diagnosis and in the current chemotherapy
group, although the differences in the EQ-5D-3L index
between groups were not statistically significant. Our re-
sults corroborated the findings of Chae and Seo that pa-
tients who are younger, more highly educated, and with
a longer time since diagnosis have a higher HRQoL [22].
HRQoL score differences by age group were not consist-
ent with previous reports of HRQoL measurements in
breast cancer patients [16, 22, 23]. Age has different im-
pacts on HRQoL domains. Ahn et al’s study on breast
cancer survivors showed better social and emotional
function but poorer physical function with increasing
age [24].
The FACT-B subscale scores for problem reporting in
each EQ-5D-3L dimension were significantly different in
the current analysis. The EQ-5D-3L index was moder-
ately correlated with FACT-B subscale scores, ranging
from 0.377 at FWB to 0.553 at PWB subscales, except
for SWB. This finding was similar to those of Lee et al.
who studied patients with breast cancer in Singapore
[26]. In that study, a correlation between the EQ-5D-3L
index and FACT-B subscales was the lowest at 0.11 on
the SWB subscales and the highest at 0.66 on the PWB
subscales [26].
Reliability of EQ-5D-3L in this study was inconclusive.
Kappa values for EQ-5D-3L dimensions varied depend-
ing on domain and confidence intervals of kappa values
were wide in mobility, self-care and usual activities. The
ICCs of the EQ-5D-3L index was reasonable but EQ-
VAS were somewhat low. Kappa values on mobility di-
mensions were the lowest at 0.32, but showed some
agreement with the Landis and Koch criteria [25] at an
agreement rate of 94.4 %. Low reliability statistics could
be due to small sample size, change of health states
between 2 time periods, and high proportion of no prob-
lem in mobility, self-care and usual activities dimensions.
In the previous Singapore study, ICCs for the EQ-5D-3L
index were reported to as 0.81 in the English version
and 0.69 in the Chinese version [27]. Similarly, another
Korean study of colorectal cancer patients reported
kappa values for the EQ-5D-3L dimensions ranging from
0.32 to 0.56 and the ICC of the EQ-5D-3L index of 0.55
[13]. Compared to our present study, an earlier Taiwan
study on cervical cancer patients reported somewhat
higher kappa values for the EQ-5D-3L dimensions and
the ICC of the EQ-5D-3L index [28].
The findings of the present study cannot be general-
ized since only postoperative breast cancer patients at 1
tertiary hospital were enrolled. Another limitation was
that we did not investigate patient recurrence status,
time since treatment completion, performance status at
the visit day, or comorbidity. Because these parameters
could affect the HRQoL, more comprehensive data are
needed in the future to assess the psychometric proper-
ties of the HRQoL instruments. In addition, we did not
assess the responsiveness of the EQ-5D-3L in breast
cancer interventions; hence, further studies are war-
ranted. Lastly, we did not reassess physical status at re-
test period, thus evidence on test-retest reliability was
inconclusive.
Conclusion
In conclusion, we showed that the EQ-5D-3L could be a
valid instrument for measuring the HRQoL of post-
operative breast cancer patients in South Korea. How-
ever, reliability of the EQ-5D-3L is not conclusive and
needs further research.
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